Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
- 1 August 2011
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 47 (12), 1772-1778
- https://doi.org/10.1016/j.ejca.2011.02.013
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trialsAnnals of Oncology, 2009
- Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTsClinical Trials, 2009
- Onsite Image Evaluations and Independent Image Blinded Reads: Close Cousins or Distant Relatives?Journal of Clinical Oncology, 2009
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Recommendations for the assessment of progression in randomised cancer treatment trialsEuropean Journal of Cancer, 2009
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority studyAnnals of Oncology, 2008
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical TrialJournal of Clinical Oncology, 2008
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007